Triveni Bio, a biotech company headquartered in Waltham, MA, has secured $92 million in Series A funding to propel their cutting-edge research, especially their lead antibody program, TRIV-509, towards clinical fruition. Atlas Venture and Cormorant Asset Management led the Series A funding round, marking a crucial turning point for Triveni Bio’s innovative genetics-informed precision medicine approach.
This influx of capital underscores investors’ confidence in Triveni Bio’s vision and signals a new era in the development of tailored treatments for patients battling inflammatory and immunological conditions worldwide.
Triveni Bio, under the leadership of CEO Vishal Patel and Chief Scientific Officer Jennifer Dovey, Ph.D., is at the forefront of developing functional antibodies tailored for the treatment of inflammatory and immunological (I&I) disorders. Their lead antibody program, TRIV-509, targets kallikreins 5 and 7 (KLK5/7), presenting promising avenues for conditions like atopic dermatitis and asthma.
Funding for Future Innovation
The funding will help propel TRIV-509 from preclinical development into a Phase 2a clinical trial. Additionally, the funds will fuel a robust pipeline comprising novel antibodies. Triveni Bio aims to nominate two more development candidates by 2024, ushering in a new era of therapeutic options for patients battling I&I disorders.
Triveni Bio’s success is underpinned by collaboration and expertise. The company results from a strategic merger between Amagma Therapeutics, founded by Tillman Gerngross, Ph.D., and Leonard Zon, M.D., and Modify Therapeutics, initiated and seeded by Atlas Venture.
Jean-François Formela, M.D., a partner at Atlas Venture and Board Chair of Triveni Bio, emphasized the synergy between these entities, paving the way for a data-driven precision medicine company.
Innovative Data Platform
Triveni Bio’s approach hinges on a sophisticated data platform that harnesses public and private datasets. This platform identifies genetically validated disease nodes, predicts and stratifies patient subpopulations, and offers invaluable insights into disease mechanisms.
Collaborative efforts with Nashville Biosciences have further enhanced Triveni Bio’s understanding of these complex disorders.
Triveni Bio’s recent funding is a success for I&I disorders treatment. The backing from influential investors accelerates the development of TRIV-509 and propels the company toward pioneering more targeted and effective therapies.
As Triveni Bio continues to blend cutting-edge science with innovative partnerships, the future holds promising prospects for patients worldwide.
- Closing the gap, Herself Health raises $26M to provide personalized care for women 65+
- Endor Labs Secures $70 Million to Revolutionize Code Security
- PartsTech, a Boston-based car component startup, bags $35 million
- GreenFire Energy secures funding from French multinational company Vallourec
- Freemodel, a tech-enabled home renovation startup bags $19.5 million